Evan A. Thackaberry
Corporate Officer/Principal presso VIGIL NEUROSCIENCE, INC.
Patrimonio netto: 5 115 $ in data 31/03/2024
Profilo
Evan A.
Thackaberry is currently the Senior Vice President & Head-Early Development at Vigil Neuroscience, Inc. Prior to this, he worked as the Vice President-Non Clinical Development at Ra Pharmaceuticals, Inc. from 2017 to 2020.
Thackaberry holds a doctorate degree from the University of Wisconsin.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
VIGIL NEUROSCIENCE, INC.
0.00% | 01/03/2023 | 1 500 ( 0.00% ) | 5 115 $ | 31/03/2024 |
Posizioni attive di Evan A. Thackaberry
| Società | Posizione | Inizio |
|---|---|---|
| VIGIL NEUROSCIENCE, INC. | Corporate Officer/Principal | 01/09/2020 |
Precedenti posizioni note di Evan A. Thackaberry
| Società | Posizione | Fine |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2020 |
Formazione di Evan A. Thackaberry
| University of Wisconsin | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| VIGIL NEUROSCIENCE, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Evan A. Thackaberry
